US 5,413,923 · Granted 1995-05-09
Homologous recombination for universal donor cells and chimeric mammalian hosts
Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the β 2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies.
Patent details
- Publication number
- US 5,413,923
- Filing date
- 1992-12-11
- Grant date
- 1995-05-09
- Assignee
- Cell Genesys, Inc. / Univ. Of North Carolina At Chapel Hill
- Inventor(s)
- KUCHERLAPATI; RAJU, KOLLER; BEVERLY H., SMITHIES; OLIVER
- CPC class
- C12N15/8509
Want to file your own patent?
Run your idea through our free scanner — we’ll show you which existing patents are conceptually closest, including this one if it’s a match.
Free patentability scanRelated patents in this cluster
- US 5,633,425: Transgenic non-human animals capable of producing heterologous antibodies
- US 5,545,807: Production of antibodies from transgenic animals
- US 5,661,016: Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
- US 6,075,181: Human antibodies derived from immunized xenomice